NCT00508820 - An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP | Biotech Hunter

Enrollment

407

Participants

Timeline

Start Date

February 1, 2005

Primary Completion Date

January 1, 2011

Study Completion Date

March 1, 2011

Conditions

Idiopathic Thrombocytopenic PurpuraThrombocytopeniaThrombocytopenic Purpura

Interventions

BIOLOGICAL

Romiplostim

Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.